Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Cash and Equivalents of $44.27 million for fiscal year 2025.
INOVIO PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $44.27M | -32.7% |
| 2024 | $65.81M | +359.9% |
| 2023 | $14.31M | -69.1% |
| 2022 | $46.33M | -34.9% |
| 2021 | $71.14M | -71.6% |
| 2020 | $250.73M | +1029.6% |
| 2019 | $22.20M | -6.3% |
| 2018 | $23.69M | -0.4% |
| 2017 | $23.79M | +24.3% |
| 2016 | $19.14M | -66.8% |
| 2015 | $57.63M | +42.1% |
| 2014 | $40.54M | +20.2% |
| 2013 | $33.72M | +497.2% |
| 2012 | $5.65M | -67.5% |
| 2011 | $17.35M | -13.2% |
| 2010 | $20.00M | -34.0% |
| 2009 | $30.30M | +114.6% |
| 2008 | $14.12M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.57M | +68.6% | +50.2% |
| June 30, 2025 | $24.35M | -29.2% | -39.0% |
| March 31, 2025 | $39.92M | +103.6% | -39.4% |
| December 31, 2024 | $65.81M | +359.9% | +203.5% |
| September 30, 2024 | $21.69M | +15.3% | -36.9% |
| June 30, 2024 | $34.39M | -34.8% | +75.5% |
| March 31, 2024 | $19.60M | -30.6% | +37.0% |
| December 31, 2023 | $14.31M | -69.1% | -23.9% |
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -32.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, INOVIO PHARMACEUTICALS, INC.’s cash and equivalents has grown by 213.7% (from $14.12 million to $44.27 million).
- The most recent figure is from INOVIO PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: